生脉注射液对肺癌合并冠心病患者炎症介质及肿瘤标志物的影响

Effects of Shengmai Injection on Inflammatory Mediators and Tumor Markers in Patients with Lung Cancer Complicated with Coronary Heart Disease Undergoing Chemotherapy

目的:探讨生脉注射液对肺癌合并冠心病患者炎症因子及肿瘤标志物的影响。方法:选取2019年10月~2022年1月期间本院肿瘤科收治的90例肺癌合并冠心病患者作为研究对象,采用随机数字表法分为对照组和观察组,每组45例。所有患者均接受常规化疗,对照组在常规化疗基础上给予常规对症治疗,观察组在对照组基础上给予生脉注射液治疗,比较两组临床疗效、炎症因子水平[血清中肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和超敏C反应蛋白(hs-CRP)]、肿瘤标志物水平[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和糖类抗原125(CA125)]、免疫功能指标(血清中CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))及不良反应发生情况。结果:观察组临床治疗总有效率(95.56%)高于对照组(77.78%,P<0.05)。治疗前,两组血清中TNF-α、IL-6、hs-CRP等炎症因子水平比较无统计学差异(P>0.05);治疗后,观察组各指标水平均低于对照组(P<0.05)。治疗前,两组血清中CEA、NSE、CA125等肿瘤标志物水平比较无统计学差异(P>0.05);治疗后,观察组各指标表达水平均低于对照组(P<0.05)。治疗前,两组血清中CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)等免疫功能指标表达水平比较无统计学差异(P>0.05);治疗后,两组血清中CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均降低,且观察组高于对照组(P<0.05),而CD8^(+)均升高,且观察组低于对照组(P<0.05)。观察组不良反应总发生率(15.56%)低于对照组(42.22%,P<0.05)。结论:生脉注射液临床疗效较佳,可有效降低肺癌合并冠心病患者血清中炎症因子和肿瘤标志物水平,改善患者免疫功能,且安全性较高。

Objective:To investigate the effects of Shengmai injection on inflammatory mediators and tumor markers in patients with lung cancer complicated with coronary heart disease undergoing chemotherapy.Methods:A total of 90 patients with lung cancer combined with coronary heart disease undergoing chemotherapy who were admitted to the oncology department of our hospital from October 2019 to January 2022 were selected as the research subjects,and divided into the control group and the observation group by random number table method,with 45 cases in each group.All patients received conventional chemotherapy,the control group was given conventional symptomatic treatment on the basis of conventional chemotherapy,and the observation group was given Shengmai injection on the basis of the control group.The clinical efficacy,serum levels of inflammatory factors such as tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and hypersensitive C reactive protein(hs-CRP),tumor marker levels such as carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and carbohydrate antigen 125(CA125),serum levels of immune function indicators such as CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and adverse reactions were compared between the two groups.Results:The total clinical effective rate(95.56%)of the observation group was higher than that of the control group(77.78%,P<0.05).Before treatment,there was no significant difference in the levels of TNF-α,IL-6,hs-CRP and other inflammatory factors in serum between the two groups(P>0.05).After treatment,the levels of each index in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference in serum levels of CEA,NSE,CA125 and other tumor markers between the two groups(P>0.05);after treatment,the expression levels of each index in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no statistical comparison of the expression levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and other immune function indexes in the serum of the two groups;after treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)ratio in serum of the observation group were lower than those of the control group(P<0.05),and the level of CD8^(+)in the serum of the observation group was higher than that of the control group(P<0.05).The total incidence of adverse reactions in the observation group(15.56%)was lower than that in the control group(42.22%,P<0.05).Conclusion:Shengmai injection has significant clinical efficacy,can effectively reduce the levels of inflammatory factors and tumor markers in serum of patients with lung cancer complicated with coronary heart disease undergoing chemotherapy,and improve the immune function of patients with high safety.